Yayıncı "FUTURE MEDICINE LTD" Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed için listeleme
Toplam kayıt 1, listelenen: 1-1
-
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
(FUTURE MEDICINE LTD, 2023)Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...